Here's a statement of the obvious: The opinions expressed here are those of the participants, not those of the Mutual Fund Observer. We cannot vouch for the accuracy or appropriateness of any of it, though we do encourage civility and good humor.
Dunno, but seems a bit hypish to me. A good drug for healthcare associated or aquired pneumonias would be important, but an indication for skin infections and complicated UTIs is a bit ho-hum. Their drug reps may push it hard, but the insurances will push back just as hard (and not entirely inappropriately, although their motives are never pure). The charges for some of the new stuff are staggering. Unfortunately, the relatively limited market for new antibiotics means the profits are restrained, so research is less rewarding. Probably need government support before the bacteria get ahead of us. If or when they do, some of the angst over Social Security under funding may diminish as one of the four horsemen reaps his harvest.
Always happy to see biotech pushed up, since my Fido fund needs wings.
Comments
Unfortunately, the relatively limited market for new antibiotics means the profits are restrained, so research is less rewarding. Probably need government support before the bacteria get ahead of us. If or when they do, some of the angst over Social Security under funding may diminish as one of the four horsemen reaps his harvest.
Always happy to see biotech pushed up, since my Fido fund needs wings.